checkAd

XPhyto Provides Update on Integration of 3a-diagnostics GmbH

VANCOUVER, BC and UTTENWEILER, GERMANY / ACCESSWIRE / January 24, 2022 / XPhyto Therapeutics Corp. (CSE:XPHY)(OTCQB:XPHYF)(FSE:4XT) ("XPhyto" or the "Company") is pleased to provide an update on the integration of 3a-diagnostics GmbH ("3a") into XPhyto's German operations.

 

The acquisition of 3a, announced December 6, 2021, is a primary driver of XPhyto's recent management activities in Germany. The Company has been working diligently to expedite the launch of its COVID-ID lab test system into the European market. The COVID-ID lab is a flexible and rapid 20 minute-RT-PCR test. The Company is facilitating sales activities inside and outside Germany, particularly Eastern Europe and is continuing with other EU countries as COVID-ID lab can be distributed in all countries that accept an EU CE mark. As a prerequisite for this, it was critical that 3a diagnostics be integrated into the Company. This was quickly achieved by joining forces between 3a and Vektor Pharma TF GmbH ("Vektor"), the two German science-based companies in the XPhyto portfolio.

 

The successful integration of 3a was critical to the optimization of research, development, commercialization, marketing and sales operations in Germany. It includes the harmonization of business strategies, management reorganization, and the reallocation of technical resources. As part of this process, the Company added several key human resources to drive development, commercialization and sales: Mr. Roland Spleiss, Director of Business Development, Dr. Heinrich Jehle, Head of Diagnostic Research, and Mr. Drahoslav Zdarek, Head of Sales, Europe, announced January 10th and 17th, 2021 respectively.

 

"We are now realizing significant synergies in research and development, commercialization, marketing and sales, as well as significantly improved margins for commercial products, particularly Covid-ID Lab," stated Prof. Dr. Thomas Beckert, managing director. "Vektor's qualified personnel has now assumed training, customer support, and product distribution activities from 3a, which permits 3a to focus on the development of new diagnostic products. Our next step in management optimization is the implementation of project management excellence across all product development programs, from research and development to sales and distribution."

Seite 1 von 4




0 Kommentare
Nachrichtenagentur: IRW Press
 |  398   |   |   

Schreibe Deinen Kommentar

Disclaimer

XPhyto Provides Update on Integration of 3a-diagnostics GmbH VANCOUVER, BC and UTTENWEILER, GERMANY / ACCESSWIRE / January 24, 2022 / XPhyto Therapeutics Corp. (CSE:XPHY)(OTCQB:XPHYF)(FSE:4XT) ("XPhyto" or the "Company") is pleased to provide an update on the integration of 3a-diagnostics GmbH ("3a") into …

Nachrichten des Autors

Titel
Titel
Titel
Titel